Sun Pharma has signed an exclusive agreement with LIB Therapeutics for Lerodalcibep, a cholesterol-lowering medication. This deal covers all markets globally except for the United States and China. Lerodalcibep, a once-monthly PCSK9 inhibitor, will be marketed under the name Lyrokaul in Europe.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.